Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age15+
SponsorThe First Affiliated Hospital of Soochow University
About this trial
The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with azacitidine regimen for newly diagnosed T-ALL patients.
Eligibility criteria
Qualifiers
Patients aged ≥ 15.
Patients diagnosed with T-ALL according to 2016 WHO criteria for precursor lymphoid neoplasms.
ECOG performance status score less than 3.
Patients without serious heart, lung, liver, or kidney dysfunction.
Disqualifiers
Patients who are allergic to the study drug or drugs with similar chemical structures.
Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception.
Patients with uncontrolled active infection
Patients with active bleeding.
Trial design
Treatments tested in this trial
- Venetoclax, Azacitidine
Treatment groups
28 Participants
are divided into 1 treatment groupSponsors and collaborators
The First Affiliated Hospital of Soochow University
Lead sponsor
Jining Medical University
Collaborator
The Second People's Hospital of Huai'an
Collaborator
The First Affiliated Hospital of Bengbu Medical University
Collaborator
Northern Jiangsu People's Hospital
Collaborator
Affiliated Hospital of Nantong University
Collaborator
Suzhou Hospital of Traditional Chinese Medicine
Collaborator
Source ClinicalTrials.gov